

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

☒ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>SAMANA CAPITAL, L.P.</u>			2. Issuer Name and Ticker or Trading Symbol <u>IMMUNOGEN INC</u> [ <u>IMGN</u> ]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner  Officer (give title below) Other (specify below)	
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <u>07/31/2009</u>			
(Street) <u>283 GREENWICH AVENUE</u>			4. If Amendment, Date of Original Filed (Month/Day/Year)		6. Individual or Joint/Group Filing (Check Applicable Line)  <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person	
(City)	(State)	(Zip)				

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	07/31/2009		S		3,500,000	D	\$8.64	5,525,200 <sup>(1)(2)</sup>	D <sup>(1)(2)</sup>	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
							Date Exercisable	Expiration Date					
					Code	V			Title	Amount or Number of Shares			

1. Name and Address of Reporting Person* <u>SAMANA CAPITAL, L.P.</u>													
(Last)	(First)	(Middle)											
<u>283 GREENWICH AVENUE</u>													
(Street)													
<u>GREENWICH</u>	<u>CT</u>	<u>06830</u>											
(City)	(State)	(Zip)											
1. Name and Address of Reporting Person* <u>MORTON HOLDINGS, INC.</u>													
(Last)	(First)	(Middle)											
<u>283 GREENWICH AVE</u>													
(Street)													
<u>GREENWICH</u>	<u>CT</u>	<u>06830</u>											
(City)	(State)	(Zip)											
1. Name and Address of Reporting Person* <u>KORSANT PHILIP B</u>													
(Last)	(First)	(Middle)											
<u>283 GREENWICH AVE</u>													
(Street)													
<u>GREENWICH</u>	<u>CT</u>	<u>06830</u>											

### Explanation of Responses:

2. (Continued from footnote 1) Samana Capital is the owner of record of all of the shares of ImmunoGen, Inc. common stock, par value \$0.01 per share ("Common Stock"), reported above. The Reporting Persons may each be deemed to have or share voting or investment power over 4,312,500 shares of the Common Stock reported in Column 5 above, but do not have or share voting or investment power above the remaining 1,212,700 shares of Common Stock reported in Column 5 above. Each of the Reporting Persons disclaims beneficial ownership of the shares of Common Stock reported herein, except to the extent of its respective pecuniary interests.

MORTON HOLDINGS, INC.,  
By: /s/ Catherine O'Dwyer, 07/31/2009  
Vice President of Morton  
Holdings, Inc.  
/s/ Philip B. Korsant 07/31/2009

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.